Q-omics provides the consensus-scored SPATA25 profile across patient tissues and cancer cell-line models. SPATA25 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SPATA25 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SPATA25 RNA expression shows 20,082 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, COAD, and UVM as cancer lineages where SPATA25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA25 survival associations across molecular data types. SPATA25 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA25 RNA expression–survival associations across cancer types. High SPATA25 expression shows unfavorable associations in UVM, KIRC and THCA, but favorable associations in READ, UCS and HNSC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for SPATA25 RNA expression.
This table summarizes SPATA25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA25 shows lower tumor expression in THCA, BRCA and UCEC and higher tumor expression in COAD, LIHC and CHOL. The COAD box plot shows higher SPATA25 RNA expression in tumor versus normal tissue (log2 FC = +1.142, t-test p < 0.001).
This table shows molecular features associated with SPATA25 in patient tissues and cancer cell lines. In patient samples, SPATA25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
